首页> 美国卫生研究院文献>British Journal of Pharmacology and Chemotherapy >The protective effects of CP-060S on ischaemia- and reperfusion-induced arrhythmias in anaesthetized rats
【2h】

The protective effects of CP-060S on ischaemia- and reperfusion-induced arrhythmias in anaesthetized rats

机译:CP-060S对麻醉大鼠缺血再灌注引起的心律失常的保护作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="enumerated" style="list-style-type:decimal">CP-060S is a novel sodium and calcium overload inhibitor, and is also characterized as a calcium channel blocker. As these activities have each been shown independently to ameliorate ischaemia damage in the myocardium, the combination may synergistically exert cardioprotection. In this study, therefore, the protective effect of CP-060S against ischaemia- and reperfusion-induced arrhythmia was evaluated in anesthetized rats.Rats were anaesthetized with pentobarbitone, and the left anterior descending coronary artery was occluded for either 5 min with subsequent reperfusion (a reperfusion-induced arrhythmia model) or 30 min without (an ischaemia-induced arrhythmia model). All drugs were intravenously administered 1 min before the onset of occlusion.In the reperfusion-induced arrhythmia model, the animals in the vehicle-treated group exhibited ventricular tachycardia (VT) in 100%, ventricular fibrillation (VF) in 89%, and death caused by sustained VF in 56%. CP-060S (30–300 μg kg−1) dose-dependently suppressed the incidences of arrhythmias. Significant decreases occurred at 100 μg kg−1 in VF (incidence: 42%) and mortality (8%), and at 300 μg kg−1 in VT (50%), VF (33%) and mortality (8%). This protective effect of CP-060S was 10 times more potent than that of a pure calcium channel blocker, diltiazem (30–1000 μg kg−1) we tested, in terms of effective dose ranges. As both drugs decreased myocardial oxygen consumption estimated by rate-pressure product to a similar extent, the calcium channel blocking activity of CP-060S would not seem to be sufficient to explain its potency.In the same model, co-administration of ineffective doses of diltiazem (300 μg kg−1) and a sodium and calcium overload inhibitor, (100 μg kg−1), produced significant suppression of VT (incidence: 62%), VF (46%) and mortality (8%). By contrast, co-administration of at the same dose with CP-060S (300 μg kg−1) did not add to the effect of a single treatment of CP-060S.In the ischaemia-induced arrhythmia model, CP-060S (300 μg kg−1) significantly decreased the incidence of VF from 75% to 29%, whereas diltiazem (1 mg kg−1) was ineffective.These results suggest that CP-060S inhibits both ischaemia- and reperfusion-induced arrhythmia. The combination of the calcium channel blocking effect and the calcium overload inhibition was hypothesized to contribute to these potently protective effects.
机译:class =“ enumerated” style =“ list-style-type:decimal”> <!-list-behavior =枚举前缀-word = mark-type = decimal max-label-size = 0-> CP-060S是一种新型的钠和钙超载抑制剂,也被称为钙通道阻滞剂。由于这些活性各自独立地显示出可改善心肌中的缺血性损伤,因此该组合可协同发挥心脏保护作用。因此,在本研究中,评估了麻醉大鼠中CP-060S对缺血和再灌注所致心律失常的保护作用。 用戊巴比妥麻醉大鼠,闭塞左冠状动脉前降支5分钟后再灌注(再灌注引起的心律失常模型)或30分钟不再灌注(缺血引起的心律失常模型)。所有药物在闭塞开始前1分钟静脉内给药。 在再灌注诱导的心律不齐模型中,媒介物治疗组的动物表现为100%的室性心动过速(VT),室颤(VF) )占89%,持续性室颤导致的死亡占56%。 CP-060S(30–300μg kg −1 )剂量依赖性地抑制了心律失常的发生。 VF的100Fμgkg -1 和死亡率(8%)显着下降,VT的300μgkg -1 发生(50%)显着下降),VF(33%)和死亡率(8%)。就有效剂量范围而言,CP-060S的这种保护作用是我们测试的纯钙通道阻滞剂地尔硫卓(30-1000μgkg -1 )的十倍。由于这两种药物都可以通过速率压力乘积估算出相似程度的降低心肌耗氧量,因此CP-060S的钙通道阻断活性似乎不足以解释其效价。 在同一模型中,无效剂量的地尔硫卓(300μgkg -1 )与钠和钙超载抑制剂(100μgkg -1 )并用会明显抑制VT (发生率:62%),室颤(46%)和死亡率(8%)。相比之下,与CP-060S相同剂量(300μggkgkg -1 )的共同给药并没有增加CP-060S单一治疗的效果。
  • 在缺血性心律失常模型中,CP-060S(300μgkg -1 )可以将VF的发生率从75%降至29%,而地尔硫卓(1 mg kg −1 )是无效的。 这些结果表明,CP-060S抑制缺血和再灌注引起的心律失常。推测钙通道阻滞作用和钙超载抑制作用的结合可起到这些有效的保护作用。
  • 著录项

    相似文献

    • 外文文献
    • 中文文献
    • 专利
    代理获取

    客服邮箱:kefu@zhangqiaokeyan.com

    京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
    • 客服微信

    • 服务号